insights_auto
Outlook: 55.6% bullish·0.0% bearish
Go to analysischevron_right
AGIO:NASDAQ
Agios Pharmaceuticals Inc
31,12 USD
arrow_downward
-0,81%(-0,25) 1D
10-ноя., 15:07:00 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Open
31,00 USD
High
31,58 USD
Low
30,48 USD
Mkt. cap
1,86 млд
Avg. vol.
1,29 млн
Volume
382,96 миң
52-wk high
45,99 USD
52-wk low
22,24 USD
EPS
-6,32 USD
Beta
0,66
Shares outstanding
59,81 млн
No. of employees
540
Open
31,00 USD
High
31,58 USD
Low
30,48 USD
Mkt. cap
1,86 млд
Avg. vol.
1,29 млн
Volume
382,96 миң
52-wk high
45,99 USD
52-wk low
22,24 USD
EPS
-6,32 USD
Beta
0,66
Shares outstanding
59,81 млн
No. of employees
540
News stories
From web sources and news partners
Central Oregon Daily
·
24 мүнөт мурун
Wall St retreats as hot inflation data, Fed comments fuel rate worries
Yahoo Finance
·
17 мүнөт мурун
3 Ways to Protect Your Portfolio After the S&P 500's Worst Day Since April 2025
Quantisnow
·
11 мүнөт мурун
BMO: Bank of Montreal sells S&P 500 market-linked notes due January 2028
The Motley Fool
·
2 саат мурун
Is the S&P 500 Heading for a Correction?
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc